RxDoctor Payments Data

Bertha Gaytan, MD

Family Medicine · Boerne, TXNPI 1912162033

Payments from drug & device makers

$841in general payments, 2019–2025

Across 37 payments — averaging $22.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$292
  • Lilly USA, LLC$132
  • Teva Pharmaceuticals USA, Inc.$109
  • AstraZeneca$82
  • Exact Sciences$55
  • GSK$55
  • plus $115 from 5 others

What the payments were for

  • Food & beverage$841100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$841 in reported general payments places this provider in the 55th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$75,549
Medicare patients
127
Services billed
1,293

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide29$35,371
OzempicSemaglutide29$33,535
TrulicityDulaglutide11$22,059
EliquisApixaban15$13,149
FarxigaDapagliflozin Propanediol12$8,808
SynthroidLevothyroxine Sodium22$1,566
Levothyroxine Sodium162$1,366
Atorvastatin Calcium123$812
Rosuvastatin Calcium37$629
Losartan Potassium73$606
Lisinopril105$604
Escitalopram Oxalate46$583
Montelukast Sodium42$490
Pantoprazole Sodium37$483
Liothyronine Sodium18$461

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$132$57,43040 claims
Novo NordiskOzempic$292$33,53529 claims
PfizerEliquis$39$13,14915 claims
AstraZenecaFarxiga$82$8,80812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Boerne

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →